Isomorphic raises $5 billion, partners with Merck

Country

United Kingdom

Isomorphic Labs Ltd has raised $5 billion in a Series C financing and expanded its pharma network under a new partnership with Merck & Co Inc. The financing was disclosed on 17 November and followed two days later by an announcement from Merck. The US company said the new research collaboration is aimed at identifying prospective small molecule candidates targeting “an oncology target of strategic importance.” 

Founded in 2021 and with headquarters in London, UK, and offices in Lausanne, Switzerland and Cambridge, US, Isomorphic has become a global enterprise investigating how artificial intelligence can deliver the next generation of medicines. This involves using AI to predict small molecule binding affinities and accurately identify binding pockets on proteins. Altogether, the company describes its technology as being more accurate and faster in generating evidence than traditional methods.

The partnership with Merck follows earlier drug discovery agreements between Isomorphic and Novartis, Eli Lilly and Co, and Johnson and Johnson Inc. The UK company also has a proprietary portfolio of therapeutic candidates, the identities of which haven’t been disclosed. In announcing the Series C financing, Isomorphic said that its simulation AI models are “addressing some of the most challenging problems in the industry.” These include programmes in both oncology and immunology. 

The agreement with Merck includes undisclosed upfront and milestone payments as well as tiered royalties on net sales. Merck will contribute data capabilities and discovery experience to the project alongside Isomorphic’s modelling and compute capabilities.

The Series C funding comes just six months after Isomorphic raised $2.1 billion in a Series B round. The Series B financing was said to be the second largest equity funding for a company since the start of the biotechnology industry. According to Dealroom.co, the $5 billion Series C financing is larger than the previous financing record in Europe. The newest financing was led by Greenoaks LLC and Sequoia Capital Operations LLC.

Isomorphic is a spin-out of the DeepMind laboratory of Alphabet Inc, the parent of Google, and led by Sir Dennis Hassabis, a Nobel laureate. 

Copyright 2026 Evernow Publishing Ltd